

# 12<sup>th</sup> HEART FAILURE & CARDIORENAL METABOLIC GUIDELINES FOR U M



*A closed, interactive workshop to understand the existing Heart Failure guidelines development process & its implications in clinical practice.*

📅 **21 Nov 2024**

📍 Online

## PROGRAM

TO BETTER UNDERSTAND THE  
HEART FAILURE GUIDELINES  
PROCESS AND ITS IMPLICATIONS



**21 NOV, 2024**  
**15:30 – 18:00 CET**

**15:30-15:35**    **Welcome and summary of past discussions**

**15:35-16:20**    **Session 19**

**New trial results device approaches**

- TAVi in patients with HFrEF and moderate stenosis – D Westermann
- *General discussion on possible guidelines impact*
  
- TRILUMINATE Pivotal Trial – P Lurz
- *General discussion on possible guidelines impact*
  
- Remote monitoring: what's new (SEISMIC HF) – W Abraham
- *General discussion on possible guidelines impact*

**16:20-17:50**    **Session 20**

**New trial results pharmacological approaches**

- Aficamten and Hypertrophic Cardiomyopathy – M Maron
- *General discussion on possible guidelines impact*
  
- Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity – J Butler
- *General discussion on possible guidelines impact*
  
- The FLOW trial – N Sattar
- *General discussion on possible guidelines impact*
  
- REALIZE K – M Kosiborod
- *General discussion on possible guidelines impact*
  
- ATTR-CM – What's new – M Fontana
- *General discussion on possible guidelines impact*
  
- Impella expanded data – D Westermann
- *General discussion on possible guidelines impact*

**17:50-18:00**    **Industry Q&A**  
**Close**



22 OCT, 2024  
08:15–14:30 CEST

08:15–08:40 Session 10

## What about cancer in HF GLs

*Chairs: A Coats, S Anker*

- Defining cardio-toxicity – M Anker
- Cardiac biomarkers in oncology/adrenomedullin – E Giannitsis
- Discussion

08:40–09:40 Session 11

## Cardiomyopathies

*Chairs: C Tschöpe, S Zieroth*

- HCM – M Maron
- Cardiac amyloidosis – M Fontana
- Can real-world data inform guidelines – A Kristen
- Discussion:
- What about recommendations for combination therapies

09:40–10:20 Session 12

## HFpEF therapies

*Chairs: S Zieroth, S Anker*

- FINEARTS-HF and the meta-analyses: implications – J McMurray
- Is any “news” about Finerenone applicable to Spirolactone? (And if the answer is “yes”, is anything on steroidal MRA automatically applicable to non-steroidal MRAs?) – M Böhm
- Discussion:
- What about recommendations for treatment vs for prevention
- Is this “phenotyping” (for instance for DKD or for obesity) a pillar?

10:20–10:35 Break

10:35–11:15 Session 13

## CRT and ICD in CRM disease

*Chairs: J Cleland, A Coats, M Oliveira*

- Should the Guidelines change recommendations about primary ICDs – L Stevenson
- ICD therapy in HFrEF – what is the evidence for individualized patient selection and timing? – J Cleland
- Discussion: primary prevention ICD therapy in non-ischemic heart failure – class 1 or class 2a?
- What about CCM / ICD – J Butler

11:15–11:50 Session 14

## Remote monitoring

*Chairs: J Butler, S Anker*

- New data Cardiomems – W Abraham
- Cordella data – L Stevenson
- Remote patient management using voice recognition – W Abraham
- Discussion

11:50–12:35 Session 15 Lunch session

## Update on the iCardio Alliance Global implementation Initiative

*Chairs: J Butler, S Anker*

- Global Consensus Implementation Guidelines (gCIG): update October 2024 – V Chopra
- The iCardio Alliance consortium: update October 2024 – A Coats
- Discussion

12:35–13:10 Session 16

## Obesity management in CRM disease

*Chairs: S Anker, S Zieroth*

- STEP/SUMMIT trials: ready for guideline recommendations? – J Butler
- What about the muscle wasting discussions with weight management drugs: is this relevant for GLs? – A Coats
- Discussion – issues to cover also include the following:
- What can / should CRM GLs say about the duration of therapy with GLP1-RAs?
- Can one make GL recommendations for obesity therapy in HFrEF patients without any specific trials?

13:10–14:00 Session 17

## Interatrial shunts

*Chairs: J Butler, W Abraham, M Böhm*

- The meaning of RELIEVE-HF – G Stone
- RESPONDER-HF: what can it bring? – S Shah
- Can GL makers make statements about shunt sizes? – S Shah
- Discussion

14:00–14:30 Session 18

## Industry Q&A



21 OCT, 2024  
12:30 – 19:00 CEST

13:30–13:35 Welcome / Introductions

13:35–14:05 Session 1

## New aspects in Heart Failure and CRM Guidelines methodologies

*Chairs: S Anker, S Zieroth*

- The Classical European/US HF guidelines – G Filippatos
- The KDIGO guidelines – M Jadoul
- Canadian/Australian guidelines (using the Grade approach) – S Zieroth
- Do we need CRM guidelines? – N Sattar
- Discussion

14:05–14:40 Session 2

## General guideline concept discussion: about “Pillars” & “Breakthrough devices”

*Chairs: J Cleland, A Coats*

- What makes a therapy a pillar of therapy?
- Does the endpoints composition & structure or the statistical analysis technique matter to get a class 1 recommendation
- How do GLs make recommendations for therapies approved based on regulatory expedited review?
- Is it for GL makers relevant that a deferred GL recommendation may be better for reimbursement than a 2B recommendation?
- Can a device be a “pillar” of therapy?

14:40–15:15 Session 3

## HFrEF part 1

*Chairs: A Coats, S Zieroth*

- How to get patients on foundational therapies quickly - is the STRONG HF approach realistic?! – J Cleland
- What do guidelines makers need to replace or change a foundational therapy? – P Heidenreich
- What about a 5th and 6th pillar – G Rosano
- Discussion

15:15–15:35 Session 4

## Treatment enablement strategies

*Chairs: S Anker, S Zieroth*

- What about hyperkalemia in CRM: are the differences in perspective valid? – G Savarese
- Can a device help patients better tolerate drugs? How to prove this? – W Abraham
- Discussion

15:35–15:50 Break

15:50–16:25 Session 5

## HFrEF part 2

*Chairs: J Butler, A Anker*

- ID in HFrEF: should the GLs adopt the new definition? – P Ponikowski
- Omecamtiv mecarbil new data & approaches – J Teerlink
- Discussion

16:25–17:15 Session 6

## Devices in valvular disease

*Chairs: S Anker, W Abraham*

- M-TEER for FMR: what the GLs could/should say now? – G Stone
- Solutions for less than severe FMR? – K Witte
- Discussion
- TR therapy in 2024: ready for GLs? – P Lurz
- When are sham-controlled studies for GL recognition of PROM-outcomes needed? – JA Lindenfeld
- Discussion

17:15–17:30 Break

17:30–18:15 Session 7

## Acute and Advanced HF

*Chairs: J Butler, JA Lindenfeld, C Schulze*

- Acute HF in cardiogenic shock: the role of mechanical support – D Westermann
- Discussion:
- Should GLs emphasize assessment of prognostic factors?
- Can GLs make recommendations about escalation therapy?
- Is freedom of LVAD use a GL relevant endpoint?
- What about GDMT during MCS?

18:15–18:40 Session 8

## Outpatient management of worsening heart failure

*Chairs: I Piña, A Coats*

- What about ambulatory lung congestion assessment using ReDS – W Abraham
- Should the GLs consider ambulatory /home approaches: the example of diuretics – M Konstam
- Discussion

18:40–19:00 Session 9  
Ad hoc Q&A

## CHAIRS



William T. Abraham



Stefan D. Anker



Javed Butler



Shelley Zieroth

## FACULTY

### EUROPE

- Markus Anker
- Stefan Anker
- Michael Böhm
- John Cleland
- Andrew Coats
- Gerasimos Filippatos
- Marianna Fontana
- Evangelos Giannitsis
- Michel Jadoul
- Arnt Kristen
- Philipp Lurz
- John McMurray
- Mário Oliveira
- Piotr Ponikowski
- Giuseppe Rosano
- Naveed Sattar
- Gianluigi Savarese
- Christian Schulze
- Carsten Tschöpe

- Maurizio Volterrani
- Adriaan Voors
- Dirk Westermann
- Klaus Witte

### USA / CANADA

- William T. Abraham
- Javed Butler
- Paul A. Heidenreich
- JoAnn Lindenfeld
- Mikhail Kosiborod
- Marvin Konstam
- Martin Maron
- Ileana Piña
- Sanjiv Shah
- Lynne Stevenson
- Gregg Stone
- John Teerlink
- Shelley Zieroth

### ASIA

- Carolyn Lam Su Ping
- Vijay Chopra

### FDA

- Andrew Farb
- Jordan Pomeroy
- Mary Ross Southwork
- Norman Stockbridge
- Bram Zuckerman

